Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type

Brain Imaging and Behavior

Volumn 9, Issue 2, 2015, Pages 275-284

  Stouten Kemperman, Myrle M ^a,b   de Ruiter, Michiel B ^a,b   Koppelmans, Vincent ^a,c   Boogerd, Willem ^a   Reneman, Liesbeth ^b   Schagen, Sanne B ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Breast Cancer; Chemotherapy; Cognition; Late effects; MRI

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN SIZE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DRUG MEGADOSE; FEMALE; FRACTIONAL ANISOTROPY; GRAY MATTER; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MEASUREMENT; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; VERBAL MEMORY; WHITE MATTER; BRAIN; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; RADIATION RESPONSE; SURVIVOR; THREE DIMENSIONAL IMAGING;

BRAIN; BREAST NEOPLASMS; DIFFUSION TENSOR IMAGING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAY MATTER; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SURVIVORS; WHITE MATTER;

EID: 84929951674     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-014-9305-0     Document Type: Article

References (38)

1. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., & de Haes, J. C. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85(5), 365–76.
2. Biglia, N., Bounous, V. E., Malabaila, A., Palmisano, D., Torta, D. M. E., D’Alonzo, M., & Torta, R. (2012). Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Euro j of cancer care, 21(4), 485–92. doi:10.1111/j.1365-2354.2011.01320.x.
3. Brown, M. S., Stemmer, S. M., Simon, J. H., Stears, J. C., Jones, R. B., Cagnoni, P. J., & Sheeder, J. L. (1998). White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR American journal of neuroradiology, 19(2), 217–21.
4. Collado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S. W., & Irwin, M. R. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical cancer research. j of the American Association for Cancer Research, 12(9), 2759–66. doi:10.1158/1078-0432.CCR-05-2398.
5. Conroy, S. K., McDonald, B. C., Smith, D. J., Moser, L. R., West, J. D., Kamendulis, L. M., & Saykin, A. J. (2013). Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat, 137(2), 493–502. doi:10.1007/s10549-012-2385-x.
6. De Ruiter, M. B., & Schagen, S. B. (2013). Functional MRI studies in non-CNS cancers. Brain imaging and behavior. doi:10.1007/s11682-013-9249-9.
7. De Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., van Dam, F. S., Schagen, S. B., & Nederveen, A. J. (2011). Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp, 32(8), 1206–19. doi:10.1002/hbm.21102.
8. De Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., Caan, M., Douaud, G., & Schagen, S. B. (2012). Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp, 33(12), 2971–83. doi:10.1002/hbm.21422.
9. DeCarlo, L. T. (1997). On the meaning and use of kurtosis. Psychol Methods, 2(3), 292–307. doi:10.1037//1082-989X.2.3.292.
10. Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Van den Stock, J., & Sunaert, S. (2011). Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp, 32(3), 480–93. doi:10.1002/hbm.21033.
11. Deprez, S., Billiet, T., Sunaert, S., & Leemans, A. (2013). Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. Brain imaging and behavior. doi:10.1007/s11682-012-9220-1.
12. Dietrich, J., Monje, M., Wefel, J., & Meyers, C. (2008). Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist, 13(12), 1285–95. doi:10.1634/theoncologist.2008-0130.
13. Eberling, J. L., Wu, C., Tong-Turnbeaugh, R., & Jagust, W. J. (2004). Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage, 21(1), 364–371. doi:10.1016/j.neuroimage.2003.08.037.
14. Hesbacher, P. T., Rickels, K., Morris, R. J., Newman, H., & Rosenfeld, H. (1980). Psychiatric illness in family practice. The J of clinical psychiatry, 41(1), 6–10.
15. Husain, K., Whitworth, C., Hazelrigg, S., & Rybak, L. (2003). Carboplatin-Induced Oxidative Injury in Rat Inferior Colliculus. Int J Toxicol, 22(5), 335–342. doi:10.1177/109158180302200502.
16. Jenkinson, M., Beckmann, C. F., Behrens, T. E. J., Woolrich, M. W., & Smith, S. M. (2012). FSL NeuroImage, 62(2), 782–90. doi:10.1016/j.neuroimage.2011.09.015.
17. Jim, H. S. L., Donovan, K. A., Small, B. J., Andrykowski, M. A., Munster, P. N., & Jacobsen, P. B. (2009). Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer, 115(8), 1776–83. doi:10.1002/cncr.24192.
18. Koppelmans, V., Breteler, M. M. B., Boogerd, W., Seynaeve, C., Gundy, C., & Schagen, S. B. (2012a). Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal of clinical oncology official journal of the American Society of Clinical Oncology, 30(10), 1080–6. doi:10.1200/JCO.2011.37.0189.
19. Koppelmans, V., de Ruiter, M. B., van der Lijn, F., Boogerd, W., Seynaeve, C., van der Lugt, A., & Schagen, S. B. (2012b). Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat, 132(3), 1099–106. doi:10.1007/s10549-011-1888-1.
20. Koppelmans, V., de Groot, M., de Ruiter, M. B., Boogerd, W., Seynaeve, C., Vernooij, M. W., & Breteler, M. M. B. (2014). Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp, 35(3), 889–99. doi:10.1002/hbm.22221.
21. Mangin, J.-F., Poupon, C., Clark, C., Le Bihan, D., & Bloch, I. (2002). Distortion correction and robust tensor estimation for MR diffusion imaging. Med Image Anal, 6(3), 191–8.
22. Nichols, T. E., & Holmes, A. P. (2002). Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp, 15(1), 1–25.
23. Phillips, K. M., Jim, H. S., Small, B. J., Laronga, C., Andrykowski, M. A., & Jacobsen, P. B. (2012). Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer, 118(7), 1925–32. doi:10.1002/cncr.26432.
24. Pomykala, K. L., de Ruiter, M. B., Deprez, S., McDonald, B. C., & Silverman, D. H. S. (2013). Integrating imaging findings in evaluating the post-chemotherapy brain. Brain imaging and behavior. doi:10.1007/s11682-013-9239-y.
25. Provencher, S. W. (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra Magnetic resonance in medicine. official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine, 30(6), 672–9.
26. Pullens, M. J. J., De Vries, J., & Roukema, J. A. (2010). Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho-Oncology, 19(11), 1127–38. doi:10.1002/pon.1673.
27. Rodenhuis, S., Bontenbal, M., Beex, L. V. A. M., Wagstaff, J., Richel, D. J., Nooij, M. A., & de Vries, E. G. E. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med, 349(1), 7–16. doi:10.1056/NEJMoa022794.
28. Schagen, S. B., Muller, M. J., Boogerd, W., Mellenbergh, G. J., & van Dam, F. S. A. M. (2006). Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst, 98(23), 1742–5. doi:10.1093/jnci/djj470.
29. Schilder, C. M., Eggens, P. C., Seynaeve, C., Linn, S. C., Boogerd, W., Gundy, C. M., & Schagen, S. B. (2009). Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol, 48(1), 76–85. doi:10.1080/02841860802314738.
30. Schilder, C. M., Seynaeve, C., Beex, L. V., Boogerd, W., Linn, S. C., Gundy, C. M., & Schagen, S. B. (2010). Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J of clinical oncology official journal of the American Society of Clinical Oncology, 28(8), 1294–300. doi:10.1200/JCO.2008.21.3553.
31. Schmahmann, J. D., Smith, E. E., Eichler, F. S., & Filley, C. M. (2008). Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann N Y Acad Sci, 1142, 266–309. doi:10.1196/annals.1444.017.
32. Shilling, V., & Jenkins, V. (2007). Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Euro j of oncology nursing the official j of Euro Oncology Nursing Society, 11(1), 6–15. doi:10.1016/j.ejon.2006.02.005.
33. Smith, S. M. (2002). Fast robust automated brain extraction. Hum Brain Mapp, 17(3), 143–55. doi:10.1002/hbm.10062.
34. Strick, P. L., Dum, R. P., & Fiez, J. A. (2009). Cerebellum and nonmotor function. Annu Rev Neurosci, 32, 413–34. doi:10.1146/annurev.neuro.31.060407.125606.
35. Tang, C. Y., Friedman, J., Shungu, D., Chang, L., Ernst, T., Stewart, D., & Gorman, J. M. (2007). Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC psychiatry. doi:10.1186/1471-244X-7-25.
36. Wefel, J. S., & Schagen, S. B. (2012). Chemotherapy-related cognitive dysfunction. Current neurology and neuroscience reports, 12(3), 267–75. doi:10.1007/s11910-012-0264-9.
37. Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. The lancet oncology, 12(7), 703–8. doi:10.1016/S1470-2045(10)70294-1.
38. Zhang, Y., Brady, M., & Smith, S. (2001). Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging, 20(1), 45–57. doi:10.1109/42.906424.